Compounds of Formula (I):
or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB
1
receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ
42
-related diseases and disorders.
The invention provides a novel α-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament.
The salt is represented by the general formula (I):
(wherein R is a hydrogen atom or a methoxy group; X is a halogen atom; A is selected from the group consisting of:
M is an alkali metal or an alkaline earth metal; and n is 1 when M is an alkali metal and is 2 when M is an alkaline earth metal).
本发明提供了一种新型α-卤代噻吩化合物盐,它具有强效的 LPA 受体拮抗作用,可用作药物。
该盐由通式(I)表示:
(其中 R 是氢原子或甲氧基;X 是卤素原子;A 选自以下组成的组:
M 是碱金属或碱土金属;当 M 是碱金属时,n 为 1;当 M 是碱土金属时,n 为 2)。
Halogen-substituted heterocyclic compound
申请人:UBE INDUSTRIES, LTD.
公开号:US10000463B2
公开(公告)日:2018-06-19
A novel α-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided.